NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $156.70 +1.20 (+0.77%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$158.00 +1.30 (+0.83%) As of 05/22/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neurocrine Biosciences Stock (NASDAQ:NBIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$155.44▼$158.6350-Day Range$126.32▼$161.3252-Week Range$117.59▼$162.39Volume758,737 shsAverage Volume1.33 million shsMarket Capitalization$15.76 billionP/E Ratio24.14Dividend YieldN/APrice Target$185.90Consensus RatingModerate Buy Company Overview Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities. The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. Neurocrine also commercializes Orilissa® (elagolix), a once-daily oral therapy for endometriosis, and Oriahnn® (elagolix with estradiol and norethindrone acetate) for the management of heavy menstrual bleeding associated with uterine fibroids. In addition, Neurocrine has licensed opicapone, a catechol-O-methyltransferase inhibitor for Parkinson’s disease “OFF” episodes, in partnership with BIAL. Beyond its approved products, Neurocrine maintains a diversified pipeline targeting conditions such as essential tremor, amyotrophic lateral sclerosis and Cushing’s syndrome. The company conducts clinical trials in North America, Europe and Asia, and leverages strategic partnerships to expand its global reach. This collaborative approach has enabled external commercialization agreements and regulatory submissions in multiple jurisdictions. Leadership at Neurocrine is headed by President and Chief Executive Officer Kevin C. Gorman, under whose tenure the company has secured key regulatory approvals and forged licensing deals with major pharmaceutical firms. Over the years, Neurocrine has grown from a research‐focused startup into a commercial biotech organization with a mission to develop innovative therapies for challenging neurological and endocrine diseases.AI Generated. May Contain Errors. Read More Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreNBIX MarketRank™: Neurocrine Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 165th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 17 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialNeurocrine Biosciences has a consensus price target of $185.90, representing about 18.6% upside from its current price of $156.70.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth31.56% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 31.56% in the coming year, from $7.16 to $9.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 24.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 24.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.25% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 5.15.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentNeurocrine Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Neurocrine Biosciences this week, compared to 7 articles on an average week.Search InterestOnly 9 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows11 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,779,769.00 in company stock.Percentage Held by Insiders4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Stock News HeadlinesFinancial Comparison: Neurocrine Biosciences (NASDAQ:NBIX) vs. Recursion Pharmaceuticals (NASDAQ:RXRX)May 24 at 3:49 AM | americanbankingnews.comBernstein initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendationMay 23 at 11:06 AM | msn.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Kevin Charles Gorman Sells 245,088 Shares of Neurocrine Biosciences (NASDAQ:NBIX) StockMay 23 at 4:43 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Coverage Initiated by Analysts at Sanford C. BernsteinMay 23 at 3:40 AM | americanbankingnews.comInsider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Director Sells 245,088 Shares of StockMay 22 at 7:29 AM | insidertrades.comInsider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Director Sells 15,000 Shares of StockMay 19, 2026 | insidertrades.comNeurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 3,810 SharesMay 15, 2026 | insidertrades.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $141.83 on January 1st, 2026. Since then, NBIX shares have increased by 10.5% and is now trading at $156.70. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Wednesday, February, 11th. The company reported $1.88 earnings per share for the quarter, missing analysts' consensus estimates of $2.36 by $0.48. The company's revenue for the quarter was up 28.3% on a year-over-year basis. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' Board of Directors authorized a share buyback plan on Friday, February 21st 2025, which authorizes the company to repurchase $500,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its shares are undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional shareholders include Renaissance Technologies LLC (2.41%), First Trust Advisors LP (0.95%), Dimensional Fund Advisors LP (0.71%) and Bank of New York Mellon Corp (0.70%). Insiders that own company stock include Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Darin Lippoldt, Eric Benevich, William H Rastetter, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Jude Onyia, David W Boyer, Ingrid Delaet and Shalini Sharp. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings2/11/2026Today5/24/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, NBIX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees2,000Year Founded1992Price Target and Rating Average Price Target for Neurocrine Biosciences$185.90 High Price Target$246.00 Low Price Target$140.00 Potential Upside/Downside+18.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$6.49 Trailing P/E Ratio24.14 Forward P/E Ratio21.89 P/E Growth1.18Net Income$478.60 million Net Margins21.55% Pretax Margin30.22% Return on Equity19.79% Return on Assets13.82% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.85 Sales & Book Value Annual Sales$2.86 billion Price / Sales5.51 Cash Flow$5.01 per share Price / Cash Flow31.26 Book Value$33.89 per share Price / Book4.62Miscellaneous Outstanding Shares100,550,000Free Float95,925,000Market Cap$15.76 billion OptionableOptionable Beta0.34 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:NBIX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
